top of page

How prevalent Flu and Cold?

People Who Suffer from Influenza and Colds:
CANADa.png
clipart321467.png
Digital World Map
maskw.png

In Canada, it is estimated that influenza causes 12,200 hospitalizations and 3,500 deaths according to IPAC-Canada.org.

 

CDC estimates that from 2010 to 2020, flu has resulted in between 9 and 41 million illnesses and people suffer approximately 1 billion common colds annually in the US.

​

Every year worldwide influenza causes nearly 1 billion infections and between 290,000-650,00 deaths according to IPAC-Canada.org.

 

Experts predict a resurgence in flu and colds in the continuance of the COVID-19 global pandemic.

WHAT THE SCIENCE SAYS

Anti–viral studies conducted on Flu-X® have demonstrated that, unlike some currently available natural OTC cold and flu products, which have a gradual action of supporting the immune system, Flu-X’s therapeutic mechanism is to inhibit both hemagglutinin and neuraminidase, which are large glycoproteins found on the surface of a flu virus.

 

Although these can stimulate an immune response by triggering antibody production, they are, in fact, key protagonists in the contraction and development of the flu virus: 

  • Hemagglutinin attaches to the epithelial cells of the respiratory tract to initiate the infection

  • Neuraminidase acts to release viral particles  to perpetuate the infectious cycle

  • By inhibiting these, Flu-X is able a) to reduce the risk of initial infection and b) reduce the risk of further development of the disease and its symptoms.

The Clinical Trial Results

From the summary report, “A Double-Blind, Randomized, Placebo-controlled Trial of “FIu-X”, A Standardized Herbal Influenza Spray, on Influenza Patients”, published by Changchun Hospital for Infectious Diseases, December 10, 2006.

 

The results in patients with viral respiratory tract infections treated with FIu-X® compared to the controlled placebo group:

F-D copy.PNG

Reduction

  • Duration of influenza was reduced to 3 symptom days compared to 6 symptom days

  • Both incidence and duration of the influenza virus A and B were significantly reduced with Flu-X®.

UFF.png

Improvement

  • Increase in the rate of recovery to 91.5% by day three versus 11.3% 

All represent a significant therapeutic response.

bottom of page